Search the Newsreel

Immix Biopharma (NASDAQ:IMMX) Stock Price Down 4.5% - Here's Why

Immix Biopharma (NASDAQ: IMMX) shares dropped 4.5% to $10.43 on Friday, with trading volume significantly below average. This decline followed the company missing its latest quarterly earnings estimate, reporting a loss of $0.18 per share against an expected $0.17 loss. Despite the recent dip, …

Pharma Mar, S.A. : Top Fondos de inversión | PHM | ES0169501022

Pharma Mar, S.A. : Consenso de Precios Objetivo y Recomendaciones de los Analistas | PHM | ES0169501022

ETON Stock Soars After Huge Earnings Beat And Guidance Hike

Eton Pharmaceuticals (ETON) stock surged by over 40% after reporting Q2 revenue of $37.6 million, nearly double year-over-year and significantly beating consensus estimates, with adjusted EPS of $0.43. Management raised its 2026 revenue guidance to over $145 million and adjusted EBITDA margin to at …

Curanex Pharmaceuticals Inc Q2 2026: Net income $(3.29M), EPS $(0.12) — 10-Q Summary

Curanex Pharmaceuticals Inc (CURX) reported a net loss of $(3.29M) for Q2 2026, with a diluted loss per share of $(0.12), and no revenue as the company remains pre-revenue. This compares to a net loss of $(0.06M) in Q2 2025. The company completed a …

CURX: Net loss rose to $6.4M as R&D spending increased; cash shortfall raises going concern doubts

Curanex Pharmaceuticals Inc (CURX) reported a net loss of $6.4 million for the first half of 2026, primarily due to increased spending on R&D and administrative costs as its lead drug candidate progresses. The company faces significant going concern doubts as its current cash …

Conferencia de resultados del T2 de 2026 de Acumen Pharmaceuticals (ABOS): lectura de datos de ALTITUDE-AD prevista para finales de 2026

Acumen Pharmaceuticals (NASDAQ: ABOS) held its Q2 2026 earnings conference call, focusing on the upcoming Phase II ALTITUDE-AD trial results for sabirnetug, expected by late 2026. The company reported $110.2 million in cash and marketable securities, providing liquidity until early 2027, with a net …

Are You Looking for a Top Momentum Pick? Why Urogen Pharma (URGN) is a Great Choice

Urogen Pharma (URGN) is highlighted as a strong momentum pick due to its "A" Momentum Style Score from Zacks and a Zacks Rank of #2 (Buy). The article details URGN's impressive short-term and long-term price performance, outperforming both its industry and the S&P 500. …

Eton Pharmaceuticals Stock Jumps 38% as Guidance Reset Tests Valuation

Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Cue Biopharma reported its second-quarter 2026 financial results, highlighting a significant increase in revenue due to a collaboration milestone and higher expenses related to the CUE-221 development program. The company also announced the submission of an IND for CUE-221 in food allergy applications, a …

Aquamarine Financial (ORMP) discloses 6.04% Oramed ownership in 13G/A

Aquamarine Financial (Cayman) Ltd has reported a beneficial ownership of 2,512,175 shares in Oramed Pharmaceuticals Inc., which constitutes 6.04% of the common stock as of June 30, 2026. The filing, an amended Schedule 13G/A, indicates that Aquamarine holds sole voting and sole dispositive power …

Immix Biopharma (IMMX) gains 5.6% stake holder led by Eventide Asset Management

Eventide Asset Management, LLC, through its Eventide Healthcare & Life Sciences Fund, has reported a beneficial ownership of 3,891,019 shares of Immix Biopharma (IMMX) common stock, representing a 5.6% stake. This Schedule 13G filing indicates that Eventide holds sole voting and dispositive power over …

ALNY Maintains Equal-Weight by Wells Fargo -- Price Target Lowered to $256

Wells Fargo has maintained an Equal-Weight rating for Alnylam Pharmaceuticals (ALNY), lowering its price target from $316.00 to $256.00, an 18.99% decrease. Despite this, GuruFocus indicates ALNY is significantly undervalued at $223.22 compared to its GF Value™ of $528.81, showing a 57.8% undervaluation and …

West Pharmaceutical (WST) Upgraded to Buy: Here's Why

West Pharmaceutical (WST) has been upgraded to a Zacks Rank #2 (Buy) due to an upward trend in its earnings estimates. This upgrade suggests a positive outlook for the company's underlying business and could lead to a favorable impact on its stock price. The …

Eton Pharmaceuticals: No Reason Pharma Can't Deliver More Great Earnings Like These

BridgeBio Stock Has Soared 29% in Just 3 Months. Here's Why Wall Street Thinks It Could Go Even Higher.

One of the more high-flying stocks in the U.S. biotech sector these days is genetic-disease-focused BridgeBio Pharma (NASDAQ: BBIO). That's due almost entirely to the outperformance of its Attruby heart medication. If the generally bullish analyst sentiment on the company is anything to go …

What's Going On With Medipharm Labs Corp Stock Friday?

Ascendis Pharma Reports Solid Yorvipath Quarter; Yuviwel Off to Strong Start, RBC Says

Ascendis Pharma's (ASND) Q2 results showed a solid rebound for Yorvipath, while the early launch of Yuviwel in achondroplasia is progressing well, RBC Capital Markets said in a Thursday note.According to the note, Yorvipath revenue rose to 252 million euros ($291.8 million) from Silver …

Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day

Inovio Pharmaceuticals Inc. (INO) shares surged 21.10% to $1.09 on Friday, outperforming the broader market as the NASDAQ Composite Index and Dow Jones Industrial Average both experienced declines. This marked the fifth consecutive day of gains for Inovio's stock, despite a generally rough trading …

BridgeBio Pharma's Transition to Rare Disease 'Commercial Powerhouse' On Track, RBC Says

BridgeBio Pharma's (BBIO) transition into a rare disease "commercial powerhouse" is on track and poised to accelerate, RBC Capital Markets said in a Friday note.The company's Attruby drug is gaining traction in first-line treatment settings, while the market for the drug Silver Upgrade to …

Amneal Pharmaceuticals Director John Kiely Sells 50,000 Shares and Donates 10,000 Shares on August 13, 2026

John Kiely, a director at Amneal Pharmaceuticals (NASDAQ: AMRX), sold 50,000 shares of Class A Common Stock at an average price of $17.64 and donated 10,000 shares to a donor-advised fund on August 13, 2026. After these transactions, Kiely's direct ownership in the company …

NRx Pharmaceuticals nears FDA approval milestone amid expected quarterly loss and low revenue.

NRx Pharmaceuticals is anticipating a quarterly loss of $0.09 per share and revenue of $1.33 million, despite financial challenges. The company has made significant progress towards FDA approval for its preservative-free ketamine, with major regulatory risks addressed. NRx will discuss these developments and commercialization …

Nuvectis Pharma (NASDAQ:NVCT) Shares Gap Up - What's Next?

Nuvectis Pharma (NASDAQ:NVCT) shares gapped up before market open but then traded lower. The company missed its quarterly earnings expectations, reporting a wider loss than anticipated. Despite mixed analyst ratings, CEO Ron Bentsur and major shareholder Marlio Charles Mosseri recently purchased significant amounts of …

Amylyx Pharmaceuticals (AMLX) Is Down 7.1% After Wider Q2 Loss And Avexitide Phase III Update

Amylyx Pharmaceuticals reported a wider Q2 2026 net loss of US$43.42 million, though the loss per share improved. The company is advancing towards a pivotal Phase III data readout for avexitide in post-bariatric hypoglycemia, with potential commercialization targeted for 2027 if approved. This upcoming …

Latham Represents Zentalis Pharmaceuticals in US$80.5 Million Underwritten Public Offering

Latham & Watkins LLP advised Zentalis Pharmaceuticals, Inc. in its recent underwritten public offering, which is expected to generate approximately US$80.5 million in gross proceeds. The offering involved 23,000,000 shares of common stock at US$3.50 per share, with an option for underwriters to purchase …

Connect Biopharma (CNTB) investor Wei Zheng discloses 4% beneficial stake

Connect Biopharma Holdings Ltd (CNTB) investor Wei Zheng has filed an amended Schedule 13G, disclosing a beneficial ownership of 2,520,359 ordinary shares, which represents a 4% stake in the company. Zheng holds sole voting and dispositive power over these shares, with the percentage based …

Solas Capital Management (FENC) reports 1.89M Fennec shares, a 5.4% ownership stake

Solas Capital Management, LLC and Frederick Tucker Golden have reported beneficial ownership of 1,889,366 common shares of Fennec Pharmaceuticals Inc. (FENC), representing a 5.4% stake in the company. This disclosure was made via a SCHEDULE 13G/A filing. The ownership is held through a private …

Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $256.00 Price Target at Wells Fargo & Company

Wells Fargo & Company has lowered its price target for Alnylam Pharmaceuticals (NASDAQ:ALNY) from $316.00 to $256.00, while maintaining an "equal weight" rating. This adjustment implies a potential upside of 14.71% from the stock's previous close. Despite this reduction and similar moves by other …

GT Biopharma Q2 Results: Net Loss Falls To $4.5 Million

GT Biopharma (NASDAQ: GTBP) reported a Q2 2026 net loss of $4.5 million, a significant improvement from the $30.2 million loss in Q2 2025, primarily due to the absence of a non-recurring $28.7 million Greenshoe liability from the prior year. However, operational losses widened …

ARS Pharmaceuticals (NASDAQ:SPRY) Shares Gap Down on Disappointing Earnings

Theravance Biopharma (TBPH) investor group reports 17.7% beneficial stake

An investor group led by Madison Avenue International LP has reported a 17.7% beneficial stake in Theravance Biopharma, Inc. (TBPH) as of June 30, 2026. This ownership, comprising 9,212,252 Ordinary Shares, is based on 51,918,754 outstanding shares as of July 31, 2026. The group, …

Armistice Capital (IRWD) discloses 13.9M-share Ironwood Pharmaceuticals stake

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 13,932,000 shares of Ironwood Pharmaceuticals, Inc.'s Class A common stock, which represents 8.43% of the outstanding class as of June 30, 2026. This stake is held by Armistice Capital Master Fund Ltd., …

Zenas BioPharma's (ZBIO) Buy Rating Reaffirmed at Guggenheim

Guggenheim reaffirmed its "buy" rating for Zenas BioPharma (ZBIO) with a $55 price target, despite the company reporting weaker-than-expected quarterly results, including an EPS loss of $1.77 and revenue of $1 million. Analyst sentiment for ZBIO remains generally positive with a "Moderate Buy" consensus …

Estrella Immunopharma (ESLA): Armistice Capital discloses 4.99% ownership stake

Armistice Capital, LLC and Steven Boyd have disclosed a 4.99% beneficial ownership stake in Estrella Immunopharma, Inc. (ESLA) common stock. This translates to 2,051,409 shares, over which they hold shared voting and dispositive power. The shares are held by Armistice Capital Master Fund Ltd., …

Earnings call transcript: Lantern Pharma posts q2 2026 loss miss as stock slips

Lantern Pharma reported a wider-than-expected Q2 2026 net loss of $0.57 per share, primarily due to $3.6 million in non-cash warrant expenses, despite a 25% reduction in operating expenses and significant advancements in its clinical programs. The company also announced the establishment of Open-Medicine …

Armistice Capital (RIGL) reports 1.67M Rigel Pharmaceuticals shares in 13G/A

Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 1,672,000 shares of Rigel Pharmaceuticals (RIGL) common stock through a Schedule 13G/A filing. This represents 8.95% of the outstanding common stock as of June 30, 2026. The shares are held by Armistice Capital …